Theriva Biologics Inc. Cash Flow Conversion Efficiency
Theriva Biologics Inc. cash flow conversion efficiency. Based on the latest financial reports, Theriva Biologics Inc. (TOVX) has a cash flow conversion efficiency ratio of -0.159x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($15.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Theriva Biologics Inc. (1993–2025)
Cash flow conversion efficiency of Theriva Biologics Inc. from 1993 to 2025. This chart illustrates how Theriva Biologics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View TOVX live share price for real-time trading data and today's change.
Theriva Biologics Inc. Cash Flow Conversion Ratio Explained
Theriva Biologics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Theriva Biologics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theriva Biologics Inc. ranked by their cash flow conversion efficiency. Also see TOVX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stamper Oil & Gas Corp
V:STMP
|
-0.022x |
|
GGL Resources Corp
V:GGL
|
-0.023x |
|
Orcoda Ltd
AU:ODA
|
-0.059x |
|
Forum Energy Metals Corp
V:FMC
|
0.046x |
|
Kibo Energy PLC
JSE:KBO
|
-0.011x |
|
Manhattan Corporation Limited
F:32U
|
-0.016x |
|
Augros Cosmetic Packaging SA
PA:AUGR
|
-0.287x |
|
WALKER RIVER RES CORP
F:1WV0
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Theriva Biologics Inc. (1993–2025)
The table below shows the annual cash flow conversion efficiency of Theriva Biologics Inc. from 1993 to 2025. Review Theriva Biologics Inc. (TOVX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.38 Million | $-16.67 Million | -1.084x | -21.99% |
| 2024-12-31 | $19.07 Million | $-16.94 Million | -0.888x | -85.63% |
| 2023-12-31 | $39.70 Million | $-19.00 Million | -0.479x | -36.83% |
| 2022-12-31 | $54.56 Million | $-19.08 Million | -0.350x | -77.46% |
| 2021-12-31 | $65.41 Million | $-12.89 Million | -0.197x | +91.48% |
| 2020-12-31 | $5.26 Million | $-12.17 Million | -2.314x | -91.62% |
| 2019-12-31 | $11.49 Million | $-13.87 Million | -1.208x | -84.91% |
| 2018-12-31 | $26.45 Million | $-17.28 Million | -0.653x | -111.02% |
| 2017-12-31 | $-3.41 Million | $-20.20 Million | 5.925x | +147.76% |
| 2016-12-31 | $2.25 Million | $-27.90 Million | -12.406x | -378.60% |
| 2015-12-31 | $15.00 Million | $-38.89 Million | -2.592x | -54.06% |
| 2014-12-31 | $9.56 Million | $-16.08 Million | -1.683x | -231.99% |
| 2013-12-31 | $15.23 Million | $-7.72 Million | -0.507x | +25.94% |
| 2012-12-31 | $13.03 Million | $-8.92 Million | -0.684x | -68.03% |
| 2011-12-31 | $7.06 Million | $-2.88 Million | -0.407x | -27.86% |
| 2010-12-31 | $3.58 Million | $-1.14 Million | -0.319x | +61.32% |
| 2009-12-31 | $3.54 Million | $-2.92 Million | -0.824x | -14.83% |
| 2008-12-31 | $6.76 Million | $-4.85 Million | -0.717x | -29.68% |
| 2007-12-31 | $11.95 Million | $-6.61 Million | -0.553x | -175.54% |
| 2006-12-31 | $11.79 Million | $-2.37 Million | -0.201x | -113.06% |
| 2005-12-31 | $-703.84K | $-1.08 Million | 1.537x | +306.12% |
| 2002-12-31 | $-15.39 Million | $-5.82 Million | 0.379x | -57.36% |
| 2001-12-31 | $-9.09 Million | $-8.07 Million | 0.888x | -93.49% |
| 2000-12-31 | $-413.72K | $-5.65 Million | 13.647x | +156.73% |
| 1999-12-31 | $671.07K | $-16.14 Million | -24.056x | +9.95% |
| 1998-12-31 | $700.00K | $-18.70 Million | -26.714x | -977.19% |
| 1997-12-31 | $-2.20 Million | $-6.70 Million | 3.045x | +186.29% |
| 1996-12-31 | $1.70 Million | $-6.00 Million | -3.529x | +15.29% |
| 1995-12-31 | $1.80 Million | $-7.50 Million | -4.167x | -146.30% |
| 1994-12-31 | $-500.00K | $-4.50 Million | 9.000x | +511.43% |
| 1993-12-31 | $1.60 Million | $-3.50 Million | -2.188x | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more